CRISPR Therapeutics AG (LTS:0VRQ) Inventories, Work In Process: $0.00 Mil (As of Mar. 2026)


LTS:0VRQ CRISPR Therapeutics AG LTS:0VRQ
45 GF Score
Price $54.15
GF Value $2.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Inventories, Work In Process?

CRISPR Therapeutics AG LTS:0VRQ -0.13% 45 Inventories, Work In Process is $0.00 Mil as of Mar. 2026. GuruFocus rates LTS:0VRQ with a GF Score™ of 45/100 and a GF Value™ of $2.41 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. CRISPR Therapeutics AG's work in process for the quarter that ended in Mar. 2026 was $0.00 Mil.

CRISPR Therapeutics AG Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Inventories, Work In Process Chart

CRISPR Therapeutics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CRISPR Therapeutics AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0VRQ
45GF Score
CRISPR Therapeutics AG LTS:0VRQ
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of $0.00 Mil mean?
CRISPR Therapeutics AG (LTS:0VRQ) has a Inventories, Work In Process of $0.00 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Inventories, Work In Process too high?
CRISPR Therapeutics AG's current Inventories, Work In Process is $0.00 Mil. Overall, CRISPR Therapeutics AG has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Inventories, Work In Process compare to CGON and XENE?
CRISPR Therapeutics AG's Inventories, Work In Process of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Inventories, Work In Process is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.41, compared to a current price of $54.15 — trading 2146.9% above its estimated fair value. The current Inventories, Work In Process is $0.00 Mil. CRISPR Therapeutics AG's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Inventories, Work In Process is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CRISPR Therapeutics AG (LTS:0VRQ) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of $54.15 is trading 2146.9% above its estimated GF Value™ of $2.41. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for LTS:0VRQ:

  • Inventories, Work In Process: $0.00 Mil
  • GF Value™: $2.41 vs. price of $54.15 (2146.9% above fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the LTS:0VRQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
45GF Score

Get the complete analysis for LTS:0VRQ

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.15
Price
$2.41
GF Value